Abstract
Major depressive disorder (MDD) is a serious mental illness that affects millions of people worldwide. There is now compelling evidence that the neuronal nicotinic acetylcholine receptors (nAChRs) play an important role in MDD and co-morbid alcohol or nicotine addiction. As a result, there has been growing interest for the treatment of MDD and co-morbid alcohol or nicotine use disorder by targeting nAChRs. Emerging evidence suggests that specific ligands that act at nAChRs significantly reduce depression-like behaviors in preclinical models that mimic MDD and co-morbid alcohol or nicotine use disorder. In this review, the pharmacological efficacy of nAChR ligands, such as mecamylamine, lobeline, cytisine, sazetidine-A, and others will be discussed. Overall, findings from preclinical and clinical studies included here suggest that the nAChR ligands may be of potential benefit in reducing MDD symptoms and that may aid in the prevention and treatment of MDD and co-morbid alcohol or nicotine use disorder.
Keywords: Alcohol use disorder, antidepressant, comorbidity, drug addiction, drug discovery, major depressive disorder, mood disorder, nicotinic receptor, nicotine use disorder.
CNS & Neurological Disorders - Drug Targets
Title:Targeting Brain Nicotinic Acetylcholine Receptors to Treat Major Depression and Co-Morbid Alcohol or Nicotine Addiction
Volume: 14 Issue: 5
Author(s): Shafiqur Rahman
Affiliation:
Keywords: Alcohol use disorder, antidepressant, comorbidity, drug addiction, drug discovery, major depressive disorder, mood disorder, nicotinic receptor, nicotine use disorder.
Abstract: Major depressive disorder (MDD) is a serious mental illness that affects millions of people worldwide. There is now compelling evidence that the neuronal nicotinic acetylcholine receptors (nAChRs) play an important role in MDD and co-morbid alcohol or nicotine addiction. As a result, there has been growing interest for the treatment of MDD and co-morbid alcohol or nicotine use disorder by targeting nAChRs. Emerging evidence suggests that specific ligands that act at nAChRs significantly reduce depression-like behaviors in preclinical models that mimic MDD and co-morbid alcohol or nicotine use disorder. In this review, the pharmacological efficacy of nAChR ligands, such as mecamylamine, lobeline, cytisine, sazetidine-A, and others will be discussed. Overall, findings from preclinical and clinical studies included here suggest that the nAChR ligands may be of potential benefit in reducing MDD symptoms and that may aid in the prevention and treatment of MDD and co-morbid alcohol or nicotine use disorder.
Export Options
About this article
Cite this article as:
Rahman Shafiqur, Targeting Brain Nicotinic Acetylcholine Receptors to Treat Major Depression and Co-Morbid Alcohol or Nicotine Addiction, CNS & Neurological Disorders - Drug Targets 2015; 14 (5) . https://dx.doi.org/10.2174/1871527314666150429112954
DOI https://dx.doi.org/10.2174/1871527314666150429112954 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Melphalan in Regional Chemotherapy for Locally Recurrent Metastatic Melanoma
Current Topics in Medicinal Chemistry Molecular and Cellular Mechanisms for Alzheimers Disease:Understanding APP Metabolism
Current Molecular Medicine Alterations of Sex Differentiation in Males: From Candidate Genes to Diagnosis and Treatments
Current Pharmaceutical Design The Acute Phase Protein α1-Acid Glycoprotein: A Model for Altered Glycosylation During Diseases
Current Protein & Peptide Science Patent on Biomarkers in Medical Research: A Focus on Neuropsychiatric Disorders
Recent Patents on Biomarkers Drug Metabolism and Drug Interactions: Application and Clinical Value of In Vitro Models
Current Drug Metabolism Disturbance of Apolipoprotein B100 Containing Lipoprotein Metabolism in Severe Hyperlipidemic and Lipodystrophic HIV Patients on Combined Antiretroviral Therapy: Evidences of Insulin Resistance Effect
Medicinal Chemistry Gender Differences in the Effects of Angiotensin Receptor Blockers on Cardiovascular Disease
Current Pharmaceutical Design Molecular Determinants of the Cardiometabolic Phenotype
Endocrine, Metabolic & Immune Disorders - Drug Targets Piper Sarmentosum: A New Hope for the Treatment of Osteoporosis
Current Drug Targets Allosteric Modulation of Nicotinic Acetylcholine Receptors: The Concept and Therapeutic Trends
Current Pharmaceutical Design The Impact of Diabetes on Mortality Among Elderly Patients Admitted for Treatment at a Hospital for Cardiovascular Disease in Southern Brazil
Current Diabetes Reviews Clinical and Pre-clinical Applications of the Transcendental Meditation Program® in the Prevention and Treatment of Essential Hypertension and Cardiovascular Disease in Youth and Adults
Current Hypertension Reviews Molecular Basis of Inflammation and Insulin Resistance in Obesity
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Non-Celiac Gluten Sensitivity Triggers Gut Dysbiosis, Neuroinflammation, Gut-Brain Axis Dysfunction, and Vulnerability for Dementia
CNS & Neurological Disorders - Drug Targets Proteomics Approach for Biomarker Research in Major Depression: Antidepressant Effects
Current Drug Metabolism Crosstalk Between Covid-19 and Associated Neurological Disorders: A Review
Current Neuropharmacology Molecular Basis of Familial and Sporadic Alzheimer's Disease
Current Alzheimer Research The First Case Report of Kabuki Syndrome from the National Iranian Registry of Primary Immunodeficiencies
Endocrine, Metabolic & Immune Disorders - Drug Targets A Mechanistic Overview on Male Infertility and Germ Cell Cancers
Current Pharmaceutical Design